Inventiva S.A. (IVA)
NASDAQ: IVA · Real-Time Price · USD
2.840
+0.010 (0.35%)
Feb 21, 2025, 4:00 PM EST - Market closed
Inventiva Revenue
Inventiva had revenue of 2.73M EUR in the half year ending June 30, 2024, a decrease of -19.40%. This brings the company's revenue in the last twelve months to 19.28M, down -12.56% year-over-year. In the year 2023, Inventiva had annual revenue of 23.16M with 23.12% growth.
Revenue (ttm)
19.28M EUR
Revenue Growth
-12.56%
P/S Ratio
12.49
Revenue / Employee
156,707 EUR
Employees
123
Market Cap
257.95M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 23.16M | 4.35M | 23.12% |
Dec 31, 2022 | 18.81M | 10.31M | 121.32% |
Dec 31, 2021 | 8.50M | 3.24M | 61.52% |
Dec 31, 2020 | 5.26M | -6.03M | -53.39% |
Dec 31, 2019 | 11.29M | 3.91M | 53.02% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
IVA News
- 1 day ago - Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial - GlobeNewsWire
- 11 days ago - Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update - GlobeNewsWire
- 23 days ago - Inventiva announces the publication of the results from the investigator-initiated proof-of-concept clinical trial evaluating lanifibranor in patients with T2D and MASLD in the Journal of Hepatology - GlobeNewsWire
- 4 weeks ago - Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux - GlobeNewsWire
- 4 weeks ago - Results of LEGEND evaluating lanifibranor in combination with empagliflozin in MASH selected for oral presentation at the upcoming EASL SLD Summit 2025 - GlobeNewsWire
- 2 months ago - Inventiva to present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million - GlobeNewsWire
- 2 months ago - Results of the votes of the Combined Shareholders' General Meeting of December 11, 2024 - GlobeNewsWire